Picard Medical, parent company of SynCardia Systems, has released its pre-recorded annual stockholder presentation in advance of the 2026 Annual Meeting scheduled for July 17. The presentation highlights an 85% year-over-year revenue increase and improved gross margin of 28% from year-end 2025, driven by a 116% increase in U.S. revenue. It also provides an update on the next-generation Emperor platform, which aims to eliminate the external pneumatic driver, with an initial configuration retaining an external controller and battery, and a longer-term roadmap toward a fully implantable system. Development milestones include pursuit of FDA Breakthrough Device designation, a planned Investigational Device Exemption submission in 2028, and intent to begin clinical study activities in 2029. Stockholders will vote on proposals including the election of directors, amendments to the capital structure, ratification of the independent auditor, and advisory votes on executive compensation.
Picard Medical, Inc.85% YoY revenue increase and improved gross margin to 28%
Next-gen Emperor platform development milestones including FDA Breakthrough Device pursuit